Healthcare and Medical/

Biosimilar Market 2023-2028 Demand, Competitive Analysis and Segmentation

imarc

Biosimilar Market 2023-2028 Demand, Competitive Analysis and Segmentation

According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2023-2028”, the global biosimilar market size reached US$ 16.8 Billion in 2022. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market is expected to reach US$ 77.1 Billion by 2028, exhibiting a growth rate (CAGR) of 25.9% during 2023-2028.

Biosimilars are biotherapeutic products that are particularly identical to a reference biologic drug. They are produced using living organisms and cells that have complex molecular structures. To be labeled as a biosimilar, a biological drug must be proved similar in terms of efficacy, safety, and quality. Biosimilars are comparatively more expensive than generic drugs as their production process is complex and requires considerable investments in research and development (R&D) activities.

Request for a Free PDF Sample of this Report: https://www.imarcgroup.com/biosimilar-market/requestsample

Biosimilar Market Trends:

The surging prevalence of chronic diseases, such as cancer and autoimmune diseases, especially among the geriatric population, represents one of the key factors significantly contributing to the market growth. Additionally, the growing instances of patent expiration and loss of protection in several biologic drugs are creating a positive outlook for the market. The manufacturers have to resort to approval from the regulatory authorities once their patent expires to start the production of biosimilars. Moreover, biosimilars do not require extensive marketing, as the efficacy and safety profile of their branded counterparts has already been established, which, in turn, is working in favor of the market growth. Besides this, the high costs related to innovator biologics, especially monoclonal antibodies (mAbs), have compelled governments to undertake initiatives encouraging the usage of biosimilars over branded biologics due to their cost-effectiveness, which is accelerating the market growth.

Biosimilar Market 2023-2028 Competitive Analysis and Segmentation:

Competitive Landscape With Key Players:

The competitive landscape of the Biosimilars market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Novartis
Pfizer
Teva
Celltrion
Merck & Co
Samsung Bioepis
Eli Lilly
Biocon
Reddy's Laboratories
Amgen
Boehringer Ingelheim

Key Market Segmentation:

Molecule insights:

Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa

Indication Insights:

Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility

Manufacturing Insights:

In-house Manufacturing
Contract Manufacturing

Regional Insights:

United States
Germany
France
Italy
Spain
United Kingdom
Japan
India
South Korea
Others

Ask Analyst for Customization and Explore full Report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=497&flag=C

Key Highlights of the Report:

Market Performance (2017-2022)
Market Outlook (2023-2028)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St

Brooklyn, NY 11249, USA

Email: [email protected]

Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

imarc

Aishwarya Bhasme 2023-08-02

The research provides an overview of the worldwide Biosimilar market, including market characteristics, market segmentation analysis, market size, customer landscape, and geographical landscape. com/request-sample/83592 Biosimilar Market Key Players:It then discusses the top competitors in the worldwide Biosimilar market, as well as emerging players, in detail, including market share based on revenue, demand, high-quality product makers, sales, and service providers. Key Questions Answered in the Biosimilar Market Report are: Which are the major companies in the Biosimilar market? Which region holds the largest market share in the Biosimilar market? What factors are anticipated to drive the Biosimilar market?

saikiran TBRC 2024-03-02

Learn More On The Remicade Biosimilar Market:https://www. The remicade biosimilar market size is expected to see exponential growth in the next few years. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence. The rise in the incidence of autoimmune diseases is expected to propel the growth of the remicade biosimilar market going forward. Major companies operating in the Remicade biosimilar market are developing innovative products to sustain their position in the market.

Biswadeep 2022-05-23

The Biosimilar Interleukins Global Market Report 2021-31 by The Business Research Company describes and explains the global biosimilar interleukins market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region. The biosimilar interleukins market share is expected to reach $7. id=3433&type=smp Biosimilar Interleukins Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.

Pooja tbrc 2023-07-13

The Biosimilar Interleukins Global Market Report 2023, provides comprehensive information on the biosimilar interleukins market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. id=3433&type=smp The biosimilar interleukins market is segmented: 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes North America was the largest region in the biosimilar interleukins market in 2022. Africa Biosimilar Interleukins Market 27. Key Mergers And Acquisitions In The Biosimilar Interleukins Market 29. Appendix Read Related Reports https://www.

The Global Humira Biosimilar Market Is Estimated To Be Valued At US$ 772.1 Million In 2023 And Is Expected To Exhibit A CAGR Of 25.9%

sachin sadgir 2023-10-27

Increased biosimilar penetration is expected to substantially reduce treatment costs and expand patient access to biologic therapy for various chronic conditions. Segment Analysis The global Humira Biosimilar Market biosimilar market is dominated by the rhematoid arthritis sub-segment. Currently, Humira is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and uveitis. The rheumatoid arthritis sub-segment holds the largest market share as rheumatoid arthritis is the most common chronic inflammatory condition affecting approximately 1% of the adult population globally. Regional analysis The US region currently dominates the global Humira biosimilar market with a share of over 60% in 2023.

Ruchita 2022-01-28

The global Biosimilar Insulin Market report offers a comprehensive assessment of the market for the forecast years. com/contact/download-sample-47261The Global Biosimilar Insulin Market Report is equipped with market data from 2016 to 2026. COVID-19 Impact Analysis on Biosimilar Insulin MarketThe global pandemic COVID-19 has affected the Biosimilar Insulin market directly or indirectly. Chapter 2: To profile the top manufacturers of Biosimilar Insulin, with price, sales, revenue, and global market share of Biosimilar Insulin in 2018 and 2019. Directly Purchase the Complete Global Biosimilar Insulin Market Research Report @ https://www.

WHO TO FOLLOW

MORE FROM AUTHOR

Battery Management System Market Size and Share | Industry Report 2023-2028

imarc 2023-06-13

Traffic Lights Market 2023-2028: Share, Size, Growth, Opportunity and Forecast

imarc 2023-06-09

Geospatial Analytics Market Demand, Forecast and Overview Till 2027

imarc 2023-05-25

Network as a Service Market Segmentation and Size 2023-2028

imarc 2023-05-24

Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.

Press enter to search

Santhosh 2022-05-20

The Biosimilar Lymphocyte Modulator Global Market Report 2022 covers biosimilar lymphocyte modulator market drivers, biosimilar lymphocyte modulator market trends, biosimilar lymphocyte modulator market segments, biosimilar lymphocyte modulatormarket growth rate, biosimilar lymphocyte modulatormarket major players, and biosimilar lymphocyte modulatormarket size. The global biosimilar lymphocyte modulator market size is expected to grow from $1. The biosimilar lymphocyte modulator market share is expected to reach $2. Key Mergers And Acquisitions In The Biosimilar Lymphocyte Modulator Market30. AppendixAbout The Business Research Company: The Business Research Company is a market intelligence firm that excels in company, market, and consumer research.

Ramya 2022-05-25

The Biosimilar Hormones Global Market Report 2021-31 by The Business Research Company describes and explains the global biosimilar hormones market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The Biosimilar Hormones Global Market Report 2022 covers biosimilar hormones market drivers, biosimilar hormones market trends, biosimilar hormones market segments, biosimilar hormones market growth rate, biosimilar hormones market major players, and biosimilar hormones market size. The global biosimilar hormones market size is expected to grow from $1. The biosimilar hormones market share is expected to reach $6. id=3432&type=smpBiosimilar Hormones Global Market Report 2022 is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies.

Devanand Patil 2021-10-13

Herceptin Biosimilar Market: IntroductionTrastuzumab, sold under the brand Herceptin, is a monoclonal antibody used to treat patients suffering from HER2+ve breast cancer and gastric cancers.

It is primarily administered intravenously in cancer patients.

Herceptin binds to HER2 receptors on the surface of breast cancer cells and blocks them from receiving growth signals, thereby leading to apoptosis and decrease in mutation of cells.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=82800 Key Drivers and Restraints of Global Herceptin Biosimilar MarketBreast cancer is one of the leading causes of death among women across the globe.

Increase in incidence and prevalence of gastric & breast cancer among people, especially women, is a key factor boosting the growth of the global Herceptin biosimilar market.

According to a report by the World Health Organization in 2019, nearly 627,000 women across the globe succumbed to breast cancer, which accounted for around 15% of all cancer deaths among women, in 2018.New product launches along with a number of products in pipeline for clinical trials, approval of new Herceptin biosimilar drugs by key companies, technological advancements, increase in health care expenditure, and considerable research & development activities drive the global Herceptin biosimilar market.However, lack of awareness among people about the treatment of gastric & breast cancer with Herceptin is likely to hamper the growth of the global Herceptin biosimilar market in the next few yearsRequest COVID Analysis on Herceptin Biosimilar Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=82800 Breast Cancer to Dominate Global Herceptin Biosimilar MarketIn terms of indication, the global Herceptin biosimilar market can be classified into breast cancer, gastric cancer, and othersThe breast cancer segment is projected to dominate the global Herceptin biosimilar market during the forecast period due to increase in incidence and prevalence rate of breast cancer among womenHospital Pharmacy Segment to Capture Largest Market ShareBased on distribution channel, the global Herceptin biosimilar market can be divided into hospital pharmacies, retail pharmacies, online pharmacies, oncology centers, and othersThe hospital pharmacies segment is anticipated to capture the largest market share due to rise in the number of patients admitted to hospitals & clinics for treatment and health care infrastructure provided by hospitals such as intensive care units (ICU) and ventilators.North America to Lead Global Herceptin Biosimilar MarketIn terms of region, the global Herceptin biosimilar market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & AfricaNorth America accounted for the largest market of the global Herceptin biosimilar market in 2020, followed by Europe.

Increase in number of people suffering from gastric & breast cancer, technological advancements, rise in government grants & funding, and presence of large number of key players boost the growth of the market in North America.Pre Book Herceptin Biosimilar Market Report- https://www.transparencymarketresearch.com/checkout.php?rep_id=82800=S Key Manufacturers Operating in Global Herceptin Biosimilar MarketThe global Herceptin biosimilar market was highly fragmented in 2020.

Ben Wood 2023-09-28

The increasing prevalence of autoimmune diseases, rising demand for cost-effective treatments, and patent expirations of key biologic drugs are driving the growth of the Humira biosimilar market. As a result, the Humira biosimilar market is witnessing significant growth and is expected to continue to expand in the coming years. Based on product type, the dominant segment in the Humira biosimilar market is the adalimumab segment, which is expected to hold the largest market share. In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the Humira biosimilar market. These key players play a significant role in driving market growth through their product developments, strategic collaborations, and mergers and acquisitions.

Aafiya.Khanam 2021-11-17

The newly added Remicade Biosimilar Market research report by Value Market Research disclose all the important information associated with the market such as value, growth factor, trends, market share, size, and challenges for the forecasted timeline 2020-2027. The report also covers detailed competitive landscape including company profiles of key players operating in the global market. Get more information on "Global Remicade Biosimilar Market Research Report" by requesting FREE Sample Copy athttps://www. Browse Global RemicadeBiosimilar Market Research Report with detailed TOC athttps://www. By Disease Indication· Ulcerative Colitis· Rheumatoid Arthritis· Ankylosing Spondylitis· Crohn’s Disease· Psoriatic Arthritis· Plaque PsoriasisRegional AnalysisFurthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for remicadebiosimilar in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Pooja Khodke 2024-01-29

As patent exclusivity of Humira is expiring in major markets by 2023, several pharmaceutical companies are investing in developing Humira biosimilars. The global Humira Biosimilar Market is estimated to be valued at US$ 889. This is expected to boost the humira biosimilars market growth during the forecast period. Key TakeawaysThe Global Humira Biosimilar Market Demand is expected to witness high growth during the forecast period of 2024 to 2031. Key players operating in the Humira biosimilar market are NestlÃ© S.

Report on Interferon Alpha-2a Biosimilar Market Research 2028 - Value Market Research

Sara Jones 2022-01-28

COVID-19 Impact Analysis on Interferon Alpha-2a Biosimilar Market report published by Value Market Research provides a detailed market analysis comprising market size, share, value, growth and trends for the period 2022-2028. Get more information on "Global Interferon Alpha-2a Biosimilar Market Research Report" by requesting FREE Sample Copy at https://www. Browse Global Interferon Alpha-2a Biosimilar Market Research Report with detailed TOC at https://www. By Type · Long-lasting Type · Ordinary Type By Application · Hepatitis C · Hepatitis B · OtherRegional AnalysisThis section covers the regional outlook, which accentuates current and future demand for the Interferon Alpha-2a Biosimilar market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Purchase Complete Global Interferon Alpha-2a Biosimilar Market Research Report at https://www.

Nirbhay Kulshrestha 2023-02-22

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Biosimilar Contract Manufacturing Market"The global biosimilar contract manufacturing market can be segmented by product, by technology, by application and by region. Based on the Product, the global biosimilar contract manufacturing market can be divided into Recombinant Non-glycosylated Proteins v/s Recombinant Glycosylated Proteins. Major companies operating in global biosimilar contract manufacturing market are:Catalent, Inc. “The North American region is expected to dominate in the global biosimilar contract manufacturing market due to the increasingly developed biosimilar contract organizations in the developing countries. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global biosimilar contract manufacturing market.

Edward E . Breen 2022-07-19

According to the recent report by IMARC Group, entitled “Biosimilar Market: Global Industry Trends, Size, Share, Growth, Opportunity and Forecast 2022-2027”, the biosimilars market reached a value of US$ 13. A biological drug must be proved similar in terms of safety, quality, and efficacy to be labeled as a biosimilar. Request for a PDF sample of this report: https://www. About Us:IMARC Group is a leading market research company that offers management strategy and market research worldwide. Contact Us:IMARC Group30 N Gould St Ste RSheridan, WY 82801 USA - WyomingEmail: Sales@imarcgroup.

Shashwat 2023-11-08

In 2022, the dominance region is North region in US Biosimilar market. Click here to Download a Custom ReportCompetition Scenario in US Biosimilar MarketThe US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. What is the Expected Future Outlook for the Overall US Biosimilar Market? The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors.

Charls Bawez 2023-06-22

The Remicade Biosimilar Market Research Report Forecast is a valuable source of insightful data for business strategists. The broad remicade biosimilar market has been sub-grouped into disease indication. Request a FREE Sample Copy of Remicade Biosimilar Market Report with Full TOC At: https://www. The key players in the remicade biosimilar market include Alvogen, Celltrion, Janssen Biotech, Inc. Browse Full Global Remicade Biosimilar Market Research Report With TOC At: https://www.

kashish Singh 2023-04-12

Get more information on "Global Biosimilar Monoclonal Antibody Market Research Report" by requesting FREE Sample Copy at https://www. com/contact/biosimilar-monoclonal-antibody-market/download-sampleMarket DynamicsThe reason for the biosimilar monoclonal antibody market growth is the rising prevalence of chronic diseases worldwide. Rising generic population and increasing cases of diseases like rheumatoid arthritis and cancers are contributing to the biosimilar monoclonal antibody market growth. Additionally, these tools also give an inclusive assessment of each segment in the global market of biosimilar monoclonal antibody. Purchase Complete Global Biosimilar Monoclonal Antibody Market Research Report at https://www.

Ganesh Shinde 2023-02-03

During the forecast period, the remicade biosimilar market is expected to develop at a CAGR of 35. The value of the remicade biosimilar market is expected to reach US$ 47,549. By Disease Indication:Crohn’s diseaseRheumatoid arthritisAnkylosing spondylitisPsoriatic arthritisUlcerative ColitisPlaque psoriasisRemicade Biosimilar Market: Competition AnalysisThe FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Remicade Biosimilar market. Competitive information detailed in the Remicade Biosimilar market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Remicade Biosimilar market report.

Global and China Biosimilar of Remicade Market Size, Status and Forecast 2021-2027

vivek bajaj 2021-08-09

Global Biosimilar of Remicade Scope and Market SizeBiosimilar of Remicade market is segmented by company, region (country), by Type, and by Application.

Players, stakeholders, and other participants in the global Biosimilar of Remicade market will be able to gain the upper hand as they use the report as a powerful resource.

The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-china-biosimilar-of-remicade-2021-2027-502 Segment by Type Monoclonal AntibodiesInterferonErythropoietinInsulinVaccinesOther Segment by Application TumorDiabetesCardiovascularHemophiliaOther By Region North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of AsiaLatin AmericaMexicoBrazilRest of Latin AmericaMiddle East & AfricaTurkeySaudi ArabiaUAERest of MEA By Company RocheAmgenAbbVieSanofi-AventisJohnson & JohnsonPfizerNovo NordiskEli LillyNovartisMerck3sbioChangchun High TechCP GuojianBiotechGelgenInnoventDong BaoGanleeUnited LaboratoriesGet the Complete Report & TOC @ https://www.grandresearchstore.com/ict-and-media/global-china-biosimilar-of-remicade-2021-2027-502Table of content1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global Biosimilar of Remicade Market Size Growth Rate by Type: 2016 VS 2021 VS 20271.2.2 Monoclonal Antibodies1.2.3 Interferon1.2.4 Erythropoietin1.2.5 Insulin1.2.6 Vaccines1.2.7 Other1.3 Market by Application1.3.1 Global Biosimilar of Remicade Market Share by Application: 2016 VS 2021 VS 20271.3.2 Tumor1.3.3 Diabetes1.3.4 Cardiovascular1.3.5 Hemophilia1.3.6 Other1.4 Study Objectives1.5 Years Considered2 Global Growth Trends2.1 Global Biosimilar of Remicade Market Perspective (2016-2027)2.2 Biosimilar of Remicade Growth Trends by Regions2.2.1 Biosimilar of Remicade Market Size by Regions: 2016 VS 2021 VS 20272.2.2 Biosimilar of Remicade Historic Market Share by Regions (2016-2021)2.2.3 Biosimilar of Remicade Forecasted Market Size by Regions (2022-2027)2.3 Biosimilar of Remicade Industry Dynamic2.3.1 Biosimilar of Remicade Market Trends2.3.2 Biosimilar of Remicade Market Drivers2.3.3 Biosimilar of Remicade Market Challenges2.3.4 Biosimilar of Remicade Market Restraints3 Competition Landscape by Key Players3.1 Global Top Biosimilar of Remicade Players by Revenue3.1.1 Global Top Biosimilar of Remicade Players by Revenue (2016-2021)3.1.2CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170 / +91 8087042414Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/grand-research-store/